The training of psychotherapists has begun for a clinical trial that will examine 5-MeO-DMT assisted psychotherapy in treatment-resistant depression (TRD).
A new MoU will explore a partnership to utilise MDMA-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD) in Europe.
Pacific Neuroscience Institute (PNI) has initiated its psilocybin clinical trial that will investigate whether the compound can be an effective treatment for major depressive disorder (MDD).
A review has shown that ketamine therapy is able to rapidly reduce symptoms of depression and suicidal thoughts in the short-term.
The groundbreaking study will now be expanded to explore the use of ketamine for treating binge eating disorder, compulsive sexual behaviour and internet gaming disorder.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
MindMed is expected to begin enrolling patients immediately into its proof-of-concept exploratory trial for the use of LSD to treat adult ADHD.
With the “one-size-fits-all” approach being the norm in the psychiatric industry, HMNC Brain Health is aiming to shake this up through targeted and personalised therapies powered...